Boston Scientific Corporation
Thesis
Boston Scientific generates substantial free cash flow and has recently achieved an investment grade credit rating, positioning it well for stock buybacks and acquisitions. The market undervalues the company due to past issues, but its private market value is significantly higher than its public valuation.
Did it work?
The thesis centers on a valuation gap closing (public price converging toward private market value), which can only be judged with price performance data, and none is provided; the time elapsed is also unknown. The credit-rating milestone is cited as already achieved within the thesis, and Boston Scientific has historically pursued acquisitions and buybacks, but without price data or a timeline we cannot confirm the re-rating or capital-return dynamics actually played out. With no verifiable outcome on the core claim, the verdict is inconclusive.